Claims

1. The use of vortioxetine or a pharmaceutically acceptable salt thereof in the manufacture of a first pharmaceutical composition for once daily oral administration for the treatment of depression, wherein said first pharmaceutical composition is to be administered to a patient simultaneously with a second pharmaceutical composition comprising vortioxetine or a pharmaceutically acceptable salt thereof, and wherein said simultaneous administration achieves a steady-state vortioxetine plasma level within 36 hours from said simultaneous administration in said patient which steady-state vortioxetine plasma level is essentially the same as the steady-state vortioxetine level achieved by the administration to said patient of said first composition alone.

2. The use according to claim 1, wherein said first pharmaceutical composition comprises 5 mg – 20 mg vortioxetine or a pharmaceutically acceptable salt thereof and wherein said simultaneous administration achieves a steady-state vortioxetine plasma level between 68 ng h/ml and 1625 ng h/ml vortioxetine in said patient within 24 hours from said simultaneous administration.

3. The use according to claim 1 or 2, wherein said second pharmaceutical composition is for intravenous, nasal, buccal or rectal administration.

4. The use according to claim 1, wherein said first pharmaceutical composition comprises 5 mg – 20 mg vortioxetine or a pharmaceutical acceptable salt thereof and said second pharmaceutical composition is for intravenous administration and comprises 5 mg – 20 mg vortioxetine or a pharmaceutically acceptable salt thereof to achieve a steady-state plasma level of vortioxetine between 68 ng h/ml and 1625 ng h/ml vortioxetine in said patient within 24 hours from said simultaneous administration.

5. The use according to claim 1, wherein said first pharmaceutical composition comprises 10 mg vortioxetine or a pharmaceutically acceptable salt thereof for once daily oral administration and said second pharmaceutical composition is for intravenous administration and comprises 10 mg – 20 mg vortioxetine or a pharmaceutically acceptable salt thereof, and wherein said second pharmaceutical composition is to be administered once simultaneously with the first of said oral administrations.

6. The use of vortioxetine or a pharmaceutical acceptable salt thereof in the manufacture of a pharmaceutical composition for the treatment of depression, wherein said pharmaceutical composition is to be administered to a patient simultaneously with a once daily oral pharmaceutical composition comprising vortioxetine or a pharmaceutically acceptable salt thereof, and wherein said simultaneous administration achieves a steady-state vortioxetine plasma level in said patient within 36 hours from said simultaneous administration which steady-state vortioxetine plasma level is essentially the same as the steady-state vortioxetine level achieved by administration of said oral pharmaceutical composition to said patient alone.

7. The use according to claim 6 wherein said pharmaceutical composition is to be simultaneously administered with a once daily oral pharmaceutical composition comprising 5 mg – 20 mg vortioxetine or a pharmaceutically acceptable salt thereof, and wherein said simultaneous administration achieves a steady-state plasma level of vortioxetine between 68 ng h/ml and 1625 ng h/ml vortioxetine in said patient within 24 hours from said simultaneous administration.

8. The use according to claim 6 or 7 wherein said pharmaceutical composition is for intravenous, nasal, buccal or rectal administration.

9. The use according to claim 6 wherein said pharmaceutical composition is a composition for intravenous administration comprising 5 mg – 40 mg vortioxetine or a pharmaceutically acceptable salt thereof, and wherein said pharmaceutical composition is intended for simultaneous administration with a once daily oral composition comprising 5 mg – 20 mg vortioxetine or a pharmaceutically acceptable salt thereof to achieve a steady-state plasma level of vortioxetine between 68 ng h/ml and 1625 ng h/ml vortioxetine in said patient within 24 hours from said simultaneous administration.

10. The use according to claim 6 wherein said pharmaceutical composition is for intravenous administration and comprises 14 mg – 20 mg vortioxetine or a pharmaceutically acceptable salt thereof and wherein said pharmaceutical composition is to be administered to a patient simultaneously with a once daily oral pharmaceutical composition comprising 10 mg vortioxetine or a pharmaceutically acceptable salt thereof, and wherein said pharmaceutical composition is to be administered once together with the first of said oral administrations.

11. A kit comprising an oral pharmaceutical composition comprising 5 mg – 20 mg vortioxetine or a pharmaceutical acceptable salt thereof for once daily oral administration and a pharmaceutical composition for IV administration comprising 5 mg - 40 mg vortioxetine or a pharmaceutically acceptable salt thereof.

5